All In Biotech

Drug Trial Radar · NCT02112214

Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population

Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 5,224 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,224

Planned (sponsor's estimate)

Start

Jun 2014

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
National Cancer Center, KoreaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
International Agency for Research on Cancer; Chonnam National University Hospital; Chung-Ang University Hospital; Pusan National University Hospital; Kyungpook National University Hospital; Uijeongbu St. Mary's Hospital/The Catholic University; Kangdong Sacred Heart Hospital; Incheon St.Mary's Hospital/The Catholic University; SMG-SNU Boramae Medical Center; Chuncheon Sacred Heart Hospital; Kosin University Gospel Hospital
First posted
Apr 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.

Conditions

  • Gastric Cancer
  • Helicobacter Pylori Infection

Interventions

  • 10-day bismuth-based quadruple therapyDrug

    Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days

  • PlaceboOther

    Placebo for bismuth-based quadruple therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of gastric cancer between the intervention and placebo groupsTime frame: Up to 10 years After H. pylori eradication

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Kosin University Gospel Hospital

    Busan, South Korea

  • Pusan National University Hospital

    Busan, South Korea

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • National Cancer Center

    Goyang, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Incheon St.Mary's Hospital/The Catholic University

    Incheon, South Korea

  • Kandong Sacred Heart Hospital

    Seoul, South Korea

  • SMG-SNU Boramae Medical Center

    Seoul, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Uijeongbu St. Mary's Hospital/The Catholic University

    Uijeongbu-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.